GlassScriptPhysician profile
Aeran Lee
NPI 1548859721
$4,689.74
in general payments reported to CMS, 2019-2025
18 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.02 · 2022: $81.76 · 2023: $737 · 2024: $2,623 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,777 · Travel and Lodging: $628 · Consulting Fee: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,776.95 |
| Travel and Lodging | $627.51 |
| Consulting Fee | $187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,101.41 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.16 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $477.65 | 2023-2025 | Wainua, Farxiga, Lokelma |
| Scpharmaceuticals INC. | $275.32 | 2024-2025 | |
| Novo Nordisk INC | $181.36 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Alnylam Pharmaceuticals INC. | $174.51 | 2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $153.72 | 2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $150.61 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $82.21 | 2024 | |
| Amgen INC. | $76.33 | 2022-2024 | Repatha |
| Edwards Lifesciences Corporation | $65.52 | 2022-2025 | Sapien 3 Ultra Resilia |
| Teleflex LLC | $59.76 | 2025 | |
| Kestra Medical Technology Services, INC. | $35.71 | 2023 | Assure Wcd |
| Philips North America LLC | $35.14 | 2025 | Mcot |
| Daiichi Sankyo INC. | $24.25 | 2023 | Injectafer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $24.02 | 2025 | |
| Procyrion, INC. | $17.07 | 2025 | Aortix System |
| Xeris Pharmaceuticals, INC. | $15.99 | 2023 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aeran Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.